NO20082288L - Monoklonalt anti-ADDL-antistoff og anvendelse derav - Google Patents

Monoklonalt anti-ADDL-antistoff og anvendelse derav

Info

Publication number
NO20082288L
NO20082288L NO20082288A NO20082288A NO20082288L NO 20082288 L NO20082288 L NO 20082288L NO 20082288 A NO20082288 A NO 20082288A NO 20082288 A NO20082288 A NO 20082288A NO 20082288 L NO20082288 L NO 20082288L
Authority
NO
Norway
Prior art keywords
addl
types
antibodies
disease
monoclonal anti
Prior art date
Application number
NO20082288A
Other languages
English (en)
Norwegian (no)
Inventor
Zhiqiang An
William R Strohl
Gene Kinney
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20082288L publication Critical patent/NO20082288L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20082288A 2005-10-21 2008-05-19 Monoklonalt anti-ADDL-antistoff og anvendelse derav NO20082288L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2005381125 2005-10-21
PCT/US2006/040508 WO2007050359A2 (en) 2005-10-21 2006-10-17 Anti-addl monoclonal antibody and use thereof

Publications (1)

Publication Number Publication Date
NO20082288L true NO20082288L (no) 2008-05-19

Family

ID=39671607

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082288A NO20082288L (no) 2005-10-21 2008-05-19 Monoklonalt anti-ADDL-antistoff og anvendelse derav

Country Status (8)

Country Link
EP (1) EP1940466B1 (https=)
JP (1) JP5289963B2 (https=)
CN (1) CN101291692A (https=)
AU (1) AU2006306553B9 (https=)
CA (1) CA2626783A1 (https=)
NO (1) NO20082288L (https=)
RU (1) RU2008120027A (https=)
WO (1) WO2007050359A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
ES2529174T3 (es) * 2007-06-12 2015-02-17 Ac Immune S.A. Anticuerpos humanizados para amiloide beta
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
EP2586797A3 (en) * 2007-11-27 2013-07-24 Medtronic, Inc. Humanized anti-amyloid beta antibodies
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
SG2013061528A (en) * 2008-08-14 2015-03-30 Merck Sharp & Dohme Methods for purifying antibodies using protein a affinity chromatography
BR112012014060B8 (pt) 2009-12-11 2021-07-27 Araclon Biotech Sl método para o diagnóstico da doença de alzheimer em um sujeito, para detecção da disfunção cognitiva branda ou para diferenciar a doença de alzheimer da disfunção cognitiva branda
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2593475B1 (en) * 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
US9176151B2 (en) 2010-07-14 2015-11-03 Acumen Pharmaceuticals, Inc. Antibodies, kit and method for detecting amyloid beta oligomers
US9320793B2 (en) 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
KR20140072019A (ko) * 2011-07-13 2014-06-12 머크 샤프 앤드 돔 코포레이션 체액 샘플에서의 아밀로이드 베타 올리고머의 검출 방법 및 그의 용도
JP6231263B2 (ja) * 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239797T1 (de) * 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
NZ337765A (en) * 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
EP1545582A4 (en) * 2002-10-01 2008-09-17 Univ Northwestern DIFFUSIBLE DERIVATIVES DERIVED FROM AMYLOID BETA (ADDL), ADDL SUBSTITUTE, ADDL BINDING MOLECULES, AND USES THEREOF
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US7811563B2 (en) * 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof

Also Published As

Publication number Publication date
AU2006306553B2 (en) 2011-08-25
WO2007050359A2 (en) 2007-05-03
EP1940466B1 (en) 2012-11-28
EP1940466A2 (en) 2008-07-09
JP5289963B2 (ja) 2013-09-11
AU2006306553B9 (en) 2011-09-29
CA2626783A1 (en) 2007-05-03
CN101291692A (zh) 2008-10-22
EP1940466A4 (en) 2010-04-07
RU2008120027A (ru) 2009-11-27
JP2009519895A (ja) 2009-05-21
AU2006306553A1 (en) 2007-05-03
WO2007050359A3 (en) 2007-06-21
WO2007050359A8 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
NO20082288L (no) Monoklonalt anti-ADDL-antistoff og anvendelse derav
NO20072700L (no) Anti-ADDL antistoffer og anvendelser derav
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
MX338640B (es) Anticuerpo monoclonal anti-ligando difundible derivado de amiloide beta y usos de los mismos.
WO2012045882A3 (en) Phosphospecific antibodies recognising tau
WO2010115843A3 (en) Pharmaceutical composition
MA45655A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
LUC00053I2 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2006099698A3 (en) Novel anti-plgf antibody
PH12021552334A1 (en) Antibodies to pyroglutamate amyloid-㟠and uses thereof
TR201800669T4 (tr) Alzheimer hastaliğinda tau-aracili patoloji̇ni̇n tanilanmasi ve protei̇n bazli tedavi̇si̇
AR083819A1 (es) UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
DE60336848D1 (de) Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
WO2017027685A3 (en) Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
WO2014159244A3 (en) O-GlcNAc TAU ANTIBODY AND USE THEREOF
EP1896588A4 (en) NEW A-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF
WO2010024927A3 (en) Treatment of amyloidoses using myelin basic protein and fragments thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application